1.
Hypertension management in England: a serial cross-sectional study from 1994 to 2011
by Falaschetti, Emanuela, MSc
The Lancet (British edition), 2014, Vol.383 (9932), p.1912-1919
2.
Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension
by Rothwell, Peter M, Prof
The Lancet (British edition), 2010, Vol.375 (9718), p.895-905
3.
Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-...
by Gupta, Ajay, MRCP
The Lancet (British edition), 2017, Vol.389 (10088), p.2473-2481
4.
Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents: A Meta-Analysis
by Gupta, Ajay K
Hypertension (Dallas, Tex. 1979), 2010-02, Vol.55 (2), p.399-407
5.
Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)
by Zinman, Bernard
Diabetologia, 2017-09-15, Vol.61 (1), p.48-57
6.
DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality
by Pieber, Thomas R
Diabetologia, 2017-09-15, Vol.61 (1), p.58-65
7.
May Measurement Month: a global blood pressure screening campaign
by Poulter, Neil R
The Lancet (British edition), 2017, Vol.389 (10080), p.1678-1680
8.
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Ang...
by Dahlöf, Björn
The Lancet (British edition), 2005-09-10, Vol.366 (9489), p.895-906
9.
Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial
by Welsh, Paul
Diabetologia, 2018-05-04, Vol.61 (7), p.1581-1591
10.
Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes
by Zoungas, Sophia
Diabetologia, 2014-09-17, Vol.57 (12), p.2465-2474
11.
Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials
by Mega, Jessica L, Dr
The Lancet (British edition), 2015, Vol.385 (9984), p.2264-2271
12.
Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
by Marso, Steven P., MD
The American heart journal, 2013, Vol.166 (5), p.823-830.e5
13.
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials
by Swerdlow, Daniel I, Dr
The Lancet (British edition), 2015-01-24, Vol.385 (9965), p.351-361
14.
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Car...
by Sever, Peter S
The Lancet (British edition), 2003, Vol.361 (9364), p.1149-1158
15.
Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension
by Chapman, Neil
Hypertension (Dallas, Tex. 1979), 2007-04, Vol.49 (4), p.839-845
16.
Improved hypertension management and control: Results from the health survey for England 1998
by PRIMATESTA, Paola
Hypertension (Dallas, Tex. 1979), 2001, Vol.38 (4), p.827-832
17.
Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-...
by Poulter, Neil R
The Lancet (British edition), 2005-09-10, Vol.366 (9489), p.907-913
18.
Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) – DEVOTE 1
by Marso, Steven P
The American heart journal, 2016-09, Vol.179, p.175-183
19.
Roadmap to achieve 25% hypertension control in Africa by 2025
by Twagirumukiza, Marc
Cardiovascular Journal of Africa, 2017-08-31, Vol.28 (4), p.262-273
20.
Baseline Characteristics of Patients Enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
by Mentz, Robert J
The American heart journal, 2017, Vol.187, p.1-9
